Muvon
muvon.io
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Jobs
Financials
Overview
We are builders. Products, open source, and selective partnerships.
News
Octofs 0.9.0: Line 42 Is a Lie
Octofs 0.9.0 gives every line a content-verified composite ID (N:hh) that edit tools check before touching a file, so a stale target fails loudly with the fresh content instead of silently editing the wrong line. Plus replace_all and CRLF-safe matching in
Read more
Report
MUVON Therapeutics Reports Positive Phase 2 Results for its First-in-Class Muscle Precursor Cell (MPC)-based Tissue-Engineered Therapy Showing Clinically Meaningful and ...
Read more
Report
Muvon Therapeutics AG: MUVON Therapeutics Reports Positive Phase 2 Results for its First-in-Class Muscle Precursor Cell (MPC)-based Tissue-Engineered Therapy Showing Clinically Meaningful and Statistically Significant Benefits in Stress Urinary Incon...
Zurich, Switzerland, December 03, 2025 - MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive topline results from the Phase 2 clinical trial SUISSE-MPC2 ) evaluating its
Read more
Report
Pro access
Upgrade to see all 9 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Jobs
No jobs available at this time.